In accordance with the resolution at the Annual General Meeting 2022 of ADDvise Group, the nomination committee for the Annual General Meeting 2025 shall comprise of representatives of the three largest shareholders by votes, according to the shareholders’ register as of 30 June 2024 maintained by Euroclear Sweden, and of the chairman of the board of directors. The representative appointed by the largest shareholder by votes shall be appointed chairman of the nomination committee.
The nomination committee has now been appointed and consists of the following members:
The nomination committee shall prepare proposals for the Annual General Meeting 2025 regarding chairman of the meeting, chairman and members of the board of directors, and remuneration to the directors of the board, committees and the auditor.
Shareholders can submit proposals to the nomination committee for the Annual General Meeting 2025 no later than January 31, 2025, by mail to: ADDvise Group AB, att: Nomination Committee, Grev Turegatan 30, SE-114 38 Stockholm.
The Annual General Meeting 2025 of ADDvise Group AB will be held on May 6, 2025.
For further information, please contact:
Hanna Myhrman, General Counsel
+46 709 82 92 23
hanna.myhrman@addvisegroup.se
About ADDvise Group
ADDvise is an international life science group. Operating a decentralised ownership model, we develop and acquire high quality companies within the business areas Lab and Healthcare. The Group comprises more than 20 companies and generates annual revenues of close to SEK 2 billion. ADDvise is listed on Nasdaq First North Premier Growth Market. Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the company's Certified Adviser. More information is available at www.addvisegroup.com.